Galderma reported 27.8% net sales growth and raised its 2024 guidance to 19.00%-21.00% annual expansion.
Galderma Group AG posted first-half non-GAAP earnings per share of $2.34, up 68.5% year-over-year, on net sales of $3.13 billion, a 27.8% increase. Core EBITDA rose 42.8% to $0.80 billion, with margins widening by 328 basis points to 25.6%.
The company previously guided for mid-teens sales growth in 2024. First-half performance prompted an upward revision, now targeting 19.00%-21.00% annual net sales growth.
Shares remained stable in after-hours trading following the release.